Friday, April 26, 2024
Advertisement
  1. You Are At:
  2. News
  3. India
  4. India will get COVID-19 vaccine by 2020 end if everything goes well: Health Minister

India will get COVID-19 vaccine by 2020 end if everything goes well: Health Minister

India currently has three vaccine candidates for Covid. ChAdOx1, developed by Oxford University and manufactured jointly by Serum Institute and AstraZeneca; Bharat Biotech's Covaxin, jointly developed with the ICMR and third is ZycovD by Zydus Cadila

India TV News Desk Edited by: India TV News Desk New Delhi Published on: August 23, 2020 16:48 IST
India will get COVID-19 vaccine by 2020 end if everything goes well: Health Minister
Image Source : FILE

India will get COVID-19 vaccine by 2020 end if everything goes well: Health Minister

Union Health Minister Dr Harsh Vardhan has said that if everything goes well, India would get a vaccine against the novel coronavirus by the end of this year. Three COVID-19 vaccine candidates, including two indigenous ones, are in different phases of development in India.

Providing information on the status of COVID-19 vaccines in India, the Union Health Minister said that “one of the country’s coronavirus vaccine is in the third phase of the clinical trial”, adding that a vaccine against the deadly pathogen will likely come in next 4-5 months. 

"We will know the efficacy of vaccines by then. The Oxford vaccine produced by Serum Institute of India is already being produced parallelly so that the time required to market it will be reduced to a larger extent. The other two vaccines may require at least a month more to produce it and introduce in the market in a phased manner. It is expected that if the vaccine trial results are good, we could be ready to use the vaccine by the first quarter of 2021," Dr Harsh Vardhan had said. 

India currently has three vaccine candidates for Covid-19 -- ChAdOx1, developed by Oxford University and manufactured jointly by the Serum Institute of India (SII), Pune, and AstraZeneca; Bharat Biotech's Covaxin, jointly developed with the Indian Council of Medical Research; and the third is ZycovD by Zydus Cadila.

The phase-one human clinical trials of the two indigenous COVID-19 vaccine candidates, one developed by Bharat Biotech in collaboration with ICMR and the other by Zydus Cadila Ltd, have been completed and the trials have moved to phase-two, ICMR Director General Dr Balram Bhargava had said recently.

The Serum Institute of India, which has partnered with AstraZeneca for manufacturing the COVID-19 vaccine candidate developed by the University of Oxford has been permitted for conducting its phase two and three human clinical trials in India. It is likely to start the trials next week.

In a tweet in Hindi, Vardhan said on Saturday, "I hope that if everything goes well, India will get a coronavirus vaccine by the end of this year."

India likely to get its first COVID vaccine website next week

 

Meanwhile, the apex health research body, ICMR, is in the process of developing an online vaccine portal which will provide information related to COVID-19 vaccine development in India and abroad, with the majority of the updates in several regional languages in addition to English.

The aim of creating the website is to provide all information and updates relating to the COVID-19 vaccine development on one platform as all the information in this regard is scattered as of now, Samiran Panda, Head of Epidemiology and Communicable Diseases at ICMR, told PTI on Saturday.

The idea behind making the updates available in regional languages is to make sure that every citizen is able to access the information. The portal is likely to be functional by next week, Panda said.

With a single-day spike of 69,239 infections, India's COVID-19 caseload mounted to 30,44,940 on Sunday, while the death toll climbed to 56,706 with 912 fatalities being reported in 24 hours, the data updated at 8 am showed. 

Advertisement

Read all the Breaking News Live on indiatvnews.com and Get Latest English News & Updates from India

Advertisement
Advertisement
Advertisement
Advertisement